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Interest in circulating RNAs for monitoring and diagnosing human health has grown significantly. 
There are few datasets describing baseline expression levels for total cell-free circulating RNA from 
healthy control subjects. In this study, total extracellular RNA (exRNA) was isolated and sequenced 
from 183 plasma samples, 204 urine samples and 46 saliva samples from 55 male college athletes ages 
18–25 years. Many participants provided more than one sample, allowing us to investigate variability 
in an individual’s exRNA expression levels over time. Here we provide a systematic analysis of small 
exRNAs present in each biofluid, as well as an analysis of exogenous RNAs. The small RNA profile 
of each biofluid is distinct. We find that a large number of RNA fragments in plasma (63%) and urine 
(54%) have sequences that are assigned to YRNA and tRNA fragments respectively. Surprisingly, while 
many miRNAs can be detected, there are few miRNAs that are consistently detected in all samples 
from a single biofluid, and profiles of miRNA are different for each biofluid. Not unexpectedly, saliva 
samples have high levels of exogenous sequence that can be traced to bacteria. These data significantly 
contribute to the current number of sequenced exRNA samples from normal healthy individuals.
The field of circulating extracellular molecules is rapidly growing, fueled by the potential for development of new 
diagnostic and therapeutic tools. As the field is still largely in an exploratory and descriptive phase, there are no 
standardized methods for sample collection, isolation, or analysis. It is currently unclear what the expectations 
for a good quality sample should be, and each biofluid under various disease and injury conditions will likely have 
diverse contents and different criteria for quality. Large datasets examining different biofluids, isolation methods, 
detection platforms and analysis tools are important to further our understanding of the extent and types of extra-
cellular material present in biofluids. These data will help inform us about how best to develop additional tools to 
enrich and capture specific types of information.
Circulating extracellular molecular material includes RNAs, DNA, lipids, and proteins (reviewed in refs 1–4). 
Carrying these materials to their targets, cells/tissues/organs, and protecting them from degradation, are a variety 
of extracellular vesicles, lipoproteins, and other RNA-binding proteins5–7. A growing number of isolation meth-
ods for profiling circulating extracellular molecules have been, and are being, developed. There is still consider-
able work necessary to identify the most efficient inclusive or selective protocols, depending on the downstream 
question. There is also a need for rigorous characterization of the biological functions of circulating extracellular 
RNAs.
There are few large datasets describing the extracellular contents in biofluid samples from normal controls8–13. 
Here we describe the largest dataset to date, focusing on total cell-free RNA (extracellular RNA), using next 
generation sequencing to profile the small RNA (16–32 nts) payload of human biofluids. Extracellular RNA was 
isolated and the small RNA content sequenced for 183 plasma samples, 204 urine samples and 46 saliva samples 
from 55 male college athletes ages 18–25 years. We examined the total RNA in an attempt not to exclude any 
information in our profile, as extracellular RNAs are packaged not only into extracellular vesicles, but are also 
associated with lipoproteins5 and AGO26,7.
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We profiled the RNA contents from these samples and examined the prevalence of different RNA biotypes. 
YRNA and tRNA fragments have previously been identified as abundant RNA species in extracellular vesicles and 
in biofluids14–20. We also found significant expression of YRNA and tRNA fragments in plasma and urine, respec-
tively. The reasons for such high levels of these small RNA fragments and their functions, are not yet known. 
YRNA fragments do not appear to be a part of the same regulatory pathway as miRNA or generated by Dicer21. 
They may play a role in apoptosis18,22, the degradation of misprocessed RNAs23, and/or DNA replication24. tRNA 
fragments (TRFs) can be created in response to stress (reviewed in ref. 25). tRNA fragments have also been found 
to have a unique role in displacing RNA binding proteins that can protect mRNAs from degradation26. It should 
be noted, that tRNAs also have many different modifications along them, which may interfere with their full rep-
resentation by conventional sequencing approaches27,28.
miRNAs make up a large portion of the reads generated for each sample. miRNAs typically function in 
post-transcriptional gene regulation. Their role in extracellular vesicles appears to be less well understood and is 
potentially more diverse - as a means to rapidly remove miRNA, and as a way to alter local tissue microenviron-
ment and regulate surrounding cells (reviewed in refs 3 and 29). We also detect piRNAs that repress transposable 
elements in the germline (reviewed in ref. 30). It is unknown what role piRNA play in circulating biofluids from 
normal healthy individuals. We also detect other small RNA species31 that are expressed at low levels in biofluids.
Throughout the analysis, it is important to bear in mind that sequencing data provides information on the 
proportion of RNA biotypes relative to one another in each sample, but not absolute concentrations of RNAs. 
Therefore, many of the analyses are presented as RPM or percentages of total input reads or reads mapping to the 
human genome.
Results
Summary of the input read alignments. Total cell-free RNA was isolated from plasma, urine, and saliva; 
sequencing libraries were created using the Illumina TruSeq small RNA preparation kit. We sequenced the small 
RNA contents from 183 plasma samples, 204 urine samples and 46 saliva samples taken from male college ath-
letes age 18–25. In our comparison of small RNAs in biofluids, we excluded plasma samples with < 5% miRNA 
mapped reads and urine and saliva samples with < 0.5% miRNA mapped reads (calculated from the total number 
of reads mapped to the human genome). The average number of input reads for plasma samples was ~8.9 million 
reads (median ~8.1 million reads; interquartile range/IQR; 4.7–10.5 million), average ~11.6 million reads for 
urine samples (median 10.3 million reads; IQR: 7–15.8 million), and an average of ~19 million reads for saliva 
samples (median 14.8 million reads; IQR: 10.9–22.6 million). Accordingly, 161 plasma, 159 urine, and 30 saliva 
samples fit these criteria and were included in the forthcoming analyses.
Figure 1A displays the percentage of input reads that aligned to the human genome (blue), aligned to human 
rRNA (green), were too short after adaptor removal (< 15 nucleotides; yellow), or did not align to the human 
genome (orange) for each sample in the analysis. A detailed sample list with the percentage of reads in each 
category can be found in Supplementary Table S1. After removal of reads that were too short and reads that 
Figure 1. Distribution of total input reads and reads mapped to the genome. (A) Displays the alignment of 
the input reads for each biofluid to the human genome, human rRNA, reads that were too short (< 15 nts), and 
unaligned to the human genome. (B) Displays the distribution of the reads mapped to the human genome to 
RNA biotypes: miRNA, tRNA, piRNA, protein-coding fragments, miRNA hairpins, Mt_tRNA (mitochondrial 
tRNA), oncRNA (other non coding RNA), snoRNA, snRNA, Vault RNA, YRNA, tRNA flanking regions, 3′ and 
5′ (50 bps flanking the mature tRNA sequence), more than one RNA biotype, and reads that are unassigned 
(intergenic, intronic, and overlapping with > 40 regions to the genome).
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mapped to human rRNA, the average number of reads aligned to the human genome for plasma samples were 
86% (median 93%: IQR 85–96%), 68% for urine (median 74%; IQR: 56–86%), and 32% for saliva (median 34%; 
IQR: 28–36%). The percentage of rRNA is highest in the urine samples with an average of 8% (median 6%), fol-
lowed by saliva samples with an average of 5% of the reads (median ~4%), and plasma with 1% of the total input 
reads mapping to rRNA (median < 1%). The average percentage of reads that are too short (< 15 nucleotides) in 
the saliva samples are ~18% (median 8%), in urine samples it is ~18% (median 11%), and in plasma samples it 
is 9% (median 4%). In the saliva samples, a median of ~45% of the reads are unaligned to the human genome.
Summary of small RNA biotypes. We next examined the percentage of reads assigned to abundant RNA 
categories or RNA biotypes (Fig. 1B). The reads that remain after mapping to rRNA and miRNA are mapped 
simultaneously to mature tRNAs, mature piRNAs and to all other RNA transcripts in GENCODE (Ensembl 75). 
This alignment strategy leads to a large percentage of read sequences that are identical in more than one RNA bio-
type. These sequences that overlap exactly with more than one RNA biotype, form the most abundant category of 
reads in the urine samples. The light green bars in Fig. 1B, depicting ‘reads shared’ across more than one biotype 
or position in the genome, constitute ~54% of the reads from urine samples and ~3% of aligned reads in saliva 
samples. In urine, these reads are primarily shared between tRNA and piRNA. Supplementary Table S2 provides 
a complete list of each sample and the percentage of reads going to each RNA biotype.
The RNA biotype that is most represented in plasma samples is YRNA, with a median of 63% of the reads 
mapped (IQR 52–73%). A more detailed analysis of YRNA fragments is discussed in a section below. Plasma sam-
ples have the highest percentage of reads assigned to miRNAs, when compared to urine and saliva, with a median 
of 25% (IQR: 17% to 34%; Wilcoxon p value < 1.5E-12). The urine samples have 2% of their reads assigned to 
miRNA (IQR of 1–4%) and saliva 1% reads are assigned (IQR 2–3%). A more complete statistical comparison of 
small RNA biotypes across and within biofluids, can be found in Supplementary Table S3. The grey bar denoted 
as “unassigned” refers to reads that do not have a known gene annotation, such as intergenic or intronic regions 
of the genome. This category also includes reads that multi-map to more than 40 different annotations. Saliva 
samples have the highest percentage of reads (~93%) that are unassigned.
Multiple alignments of short reads. There are several challenges to small RNA sequence analysis that 
influence the final categorization of the reads into biotypes. Many short read sequences are shared by more than 
one RNA biotype, making it difficult/impossible to resolve to a single unique RNA classification for many of the 
reads. The substantial percentage of reads shared amongst different RNA biotypes, when mapped concurrently, 
motivated us to examine these analyses more thoroughly. As was described previously, we allowed the reads to 
align across biotypes simultaneously; after removing reads that aligned to rRNA and miRNA. Similar analysis rec-
ommendations are outlined by the NIH Extracellular RNA Communication Consortium (ERCC) in Freedman 
et al.10.
We observed a substantial percentage of read sequences shared between tRNAs and piRNAs, particularly in 
the urine samples. Figure 2A displays Venn diagrams for plasma, urine and saliva samples that depict the average 
RPM (reads per million are calculated from reads mapped to the human genome), for reads mapping only to 
tRNAs, only to piRNAs and the reads mapping to both these RNA biotypes simultaneously for all three biofluids. 
Evident from the Venn diagrams, plasma samples have the lowest proportion of read sequences shared between 
tRNAs and piRNAs, 734 RPM on average shared between these two RNA biotypes. The saliva samples have on 
average 7,689 RPM mapping simultaneously to both tRNAs and piRNAs and 18,684 RPM mapping to tRNAs 
only. The urine samples have on average 417,700 RPM shared between tRNAs and piRNAs and an additional 
~116,500 RPM aligning solely to tRNA fragments. Only 370 RPM align to piRNAs, therefore, the small RNA 
profile of the urine samples appears to be dominated by tRNA fragments.
Based on the sequence of the piRNAs in piRBase and the mature tRNA sequences, we find that there are 
133 piRNAs that share sequences with less than or equal to 2 mismatches. For example in the urine sam-
ples, the top 5 piRNA sequences that share the largest number of reads with tRNAs are piR-hsa-1207, 
piR-hsa-28131, piR-hsa-24672, piR-hsa-5937, piR-hsa-5938. The sequences for the first two piRNAs dif-
fer by only one base (piR-hsa-1207: AGCATTGGTGGTTCAGTGGTAGAATTCTCGC, piR-hsa-28131: 
GGCATTGGTGGTTCAGTGGTAGAATTCTCGC), and overlap with the 5′ end of 10 Gly tRNAs at an average 
RPM of 411,839 GCATTGGTGGTTCAGTGGTAGAATTCTCGC.
The last 3 piRNAs differ by only 1–2 bases (piR-hsa-24672: TTCCCTGGTGGTCTAGTGGTTAGG 
AT TCGGC, piR-hsa-5937:  TCCCTGGTGGTCTAGTGGT TAGGAT TCGGCA, piR-hsa-5938: 
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCAC), these overlap with the 5′ end of 8 Glu tRNAs sequences 
detected at RPM of 4730. There were 26, 22, and 25 piRNA sequences, that did not overlap with other RNA bio-
types, consistently detected in 80% of the plasma, urine, and saliva samples respectively. These piRNA sequences 
shared no overlap with tRNAs.
Detailed tRNA fragments analysis. The presence of tRNA fragments cleaved from mature tRNAs in 
cells as a response to stress is known32–38. Recently tRNA fragments (tRF) have also been shown to be present in 
extracellular RNA in biofluids15,17,19. Mature tRNAs contain a number of post transcriptional modifications which 
hinder efficient sequencing by NGS27,28. A complete list of modifications can be found at the Modomics website 
(http://modomics.genesilico.pl/sequences/list/). Thus, the detection of tRNA fragments in sequenced samples 
can arise due to 2 main reasons: a) biologically induced tRNA cleavage, b) inability of the reverse transcriptase to 
process the entire tRNA strand due to the presence of modifications. Because we did not sequence these samples 
specifically with the removal of RNA modifications, we cannot distinguish between a) and b). Regardless, the 
tRNA fragments that were detected using our sequencing protocols in urine samples exceed those found in saliva 
and plasma (Wilcoxon p-value < 1.5E-15; Fig. 2B upper panel). The median tRF RPM for plasma, urine and saliva 
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are 2,912, 624,387 and 22,103 respectively (Wilcoxon p-value < 2.2E-16). Figure 2C represents the length distri-
bution of the tRF reads. In the plasma samples, there is a bimodal distribution of the reads with two clear peaks 
at 18 nts and 30–33 nts, the latter of which is found in the saliva samples. In the urine samples, there is a sizeable 
well-defined single peak at 30 nts. The presence of this peak at ~500,000 RPM is two and three orders of magni-
tude higher than the saliva and plasma samples respectively for their highest expressed tRF. The location of these 
tRFs was examined on the mature tRNA, whether it originates from the 5′ (tRF5), 3′ (tRF3) or neither end (tRFM, 
tRNA fragment middle). Table 1 summarizes the median percentage of reads originating from tRF5, tRF3 and 
Figure 2. Reads aligning to tRNA and piRNAs. (A) Read overlap between piRNA and tRNA. A large 
number of sequences detected by sequencing simultaneously align to both piRNA and tRNA. We assessed the 
distribution of reads per million mapped to the human genome and the numbers that were uniquely classified 
as piRNA, uniquely classified as tRNA, or overlapped between the two RNAs. In urine and saliva samples, there 
were few reads that exclusively mapped to piRNA. This does not rule out the presence of piRNA, but the origin 
of these sequences would have to be further investigated. (B) The upper and lower panels display the number of 
tRNA and YRNA fragments displays the number of tRNA fragments normalized as reads per million mapped 
to the human genome (RPM) found in each biofluid. Urine has very high levels of tRNA fragments compared 
to plasma and saliva, normalized as reads per million mapped to the human genome (RPM) found in each 
biofluid. Urine has very high levels of tRNA fragments compared to plasma and saliva and the lower panel 
demonstrates that there are a large number of YRNA fragments found in plasma compared to urine and saliva. 
(C and D) These two panels display the lengths for the tRNA and YRNA fragments respectively, identified in 
each biofluid and their abundance.
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tRFM. Figure S1A shows the percentages for individual tRNA fragments across all samples for all three biofluids 
as stacked bar plots. The percentages are calculated based on the total number of reads assigned to tRNAs, after 
the samples have been normalized for library size using median ratio normalization (DESeq2; ref. 39).
Table 2 summarizes the top ten expressed tRFs by amino-acid type for the three biofluids with the median 
percentage assigned shown in brackets. The rest of the tRNAs are combined and referred to as “Other tRNAs”. 
tRNAs belonging to the Gly-GCC family are the highest expressed in all three biofluids, followed by Glu-CTC in 
urine and Val-CAC in plasma and saliva. These are the sequences detected using conventional sequencing, and 
the presence of modifications may be masking other abundant tRNAs. Supplemental Figure S1B displays the 
percentage of reads assigned to different tRNAs based on the amino-acid type and the top 10 tRNA.
Detailed YRNA fragments analysis. According to ENSEMBL 75, there are 4 human YRNAs; RNY1, 
RNY3, RNY4, RNY5. There are an additional 52 transcripts which are pseudogenes based on the 4 human YRNAs 
and a further 878 predicted YRNA transcripts make up the YRNA category. As mentioned before, in the plasma 
samples ~63% of the reads assigned to the human genome align to YRNAs in our samples. The presence of YRNA 
fragments has been reported previously16–19. Figure 2B (lower panel) illustrates the proportion of reads aligning 
to YRFs in plasma exceeds those found in saliva and urine (Wilcoxin p-value < 1.3E-16). The median YRF RPM, 
based on reads mapped to the human genome, for plasma, urine and saliva are 629,023, 6,224 and 3,735 respec-
tively. Figure 2D displays the length distribution of the YRF reads. Unlike the tRFs, the YRFs have a unimodal 
distribution with a single large peak at 32 nts in all three biofluids. The majority of the YRNA fragments originate 
from the 5′ end. Table 3 summarizes the median percentage of reads arising from the YRF5, YRF3 or YRFM 
(middle) for all three biofluids. The percentages are calculated based on the total number of reads assigned to 
YRNAs, after the samples have been normalized for library size by the median ratio method of normalization. The 
Biofluid tRF5 tRF3 tRFM
Reads Assigned 
to tRNAs
Plasma 38% 30% 28% 20,643
Urine 99% 0% 1% 5,403,970
Saliva 89% 1% 10% 75,387
Table 1.  tRNA fragment analysis. The number of fragments arising from the 5′ , 3′ or middle of the tRNA 
sequence. The percentages are calculated based on the number of reads assigned to tRNAs after normalizing 
each sample for library size by the median ratio method. The median percentage of all samples is reported here 
for tRF5, tRF3, tRFM. The last column is the median number of reads assigned to tRNAs for each biofluid.
Plasma Urine Saliva
GlyGCC (18%) GlyGCC (86%) GlyGCC (24%)
ValCAC (10%) GluCTC (5%) ValCAC (24%)
ValAAC (9%) ValCAC (3%) GluCTC (11%)
ProCGG (9%) GluTTC (0.6%) GluTTC (3%)
GluCTC (8%) GlyCCC (0.5%) ValAAC (3%)
GlnTTG (5%) MetCAT (0.4%) LysCTT (3%)
ProTGG (3%) LysTTT (0.4%) LeuCAG (2%)
GlnCTG (3%) ProCGG (0.2%) HisGTG (2%)
LysCTT (2%) HisGTG (0.2%) LysTTT (1%)
GluTTC (2%) ValAAC (0.1%) AlaAGC (1%)
Other tRNAs (18%) Other tRNAs (0.6%) Other tRNAs (8%)
Table 2.  Percentage of reads assigned to the top 10 detected tRNA in each biofluid. The tRNA detected in 
each biofluid are listed and the percentage of the reads for each are shown in parentheses. It is important to note 
that what is described here are the results using conventional sequencing techniques, RNA modifications may 
prevent full profiling for some of the top tRNA.
Biofluid YRF5 YRF3 YRFM Reads assigned to YRNAs
Plasma 93% 0% 7% 5,156,001
Urine 98% 0% 2% 41,114
Saliva 84% 0% 16% 9,377
Table 3.  YRNA fragments originating from the 5′, 3′, or middle section of the YRNA sequence. The 
percentages are calculated based on the number of reads assigned to YRNAs after normalizing each sample for 
library size by the median ratio method. The median percentage of all samples is reported here for YRF5, YRF3, 
YRFM. The last column is the median number of reads assigned to YRNAs for each biofluid.
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most abundant YRF originates from the 5′ end of RNY4. It is responsible for a median 93%, 97% and 84% of the 
RPM assigned to YRFs in the plasma, urine and saliva samples respectively. The length of the most abundant YRF 
is 32, which maps to 9 YRNA annotations in ENSEMBL 75- RNY4, 2 YRNA pseudogenes, and 6 genes predicted 
by RFam.
Detailed miRNA analysis. As most laboratories focus their analysis on the miRNA contents of bioflu-
ids, we examined characteristics of this small RNA biotype in greater detail. A principal component analysis 
(PCA) of the miRNAs from each biofluid demonstrates that samples cluster primarily by biofluid type, Fig. 3A. 
The top ten miRNAs with the highest absolute loadings for the first principal component (PC1) were hsa-miR-
30a-5p, hsa-miR-1273h-3p, hsa-miR-30a-3p, hsa-miR-30c-2–3p, hsa-miR-10b-5p, hsa-miR-199a-5p, hsa-miR-
204-5p, hsa-miR-4433b-5p, hsa-miR-6852-5p and hsa-miR-126-3p. The top ten miRNAs with the highest 
absolute loadings for the second principal component (PC2) were hsa-miR-320a, hsa-miR-26b-5p, hsa-miR-421, 
hsa-miR-29a-3p, hsa-miR-450b-5p, hsa-miR-155-5p, hsa-miR-26a-5p, hsa-miR-30c-5p, hsa-miR-32-5p and 
hsa-miR-361-5p. The first and second principal components cumulatively explain ~29% of the variance in all the 
samples.
We examined the most robust miRNAs for each biofluid, requiring detection with > 10 or > 50 read counts 
in 80% of the samples for each biofluid. Most miRNAs are detectable in plasma samples, a few unique miRNAs 
are detectable in saliva and urine (Fig. 3B). Summarized in Table 4 are the number of miRNAs detected with at 
least 10 or 50 counts and the number of samples in which they are found for each biofluid. From Table 4, there are 
975 miRNAs detected in at least one of the sequenced plasma samples with > 10 counts. If we examine miRNAs 
that are consistently detected in plasma samples, we find 329 miRNAs expressed > 10 counts in 50% of the sam-
ples and only 98 miRNA detected in 100% of the plasma samples. 545 miRNAs are detected in at least one urine 
sample, and 122 miRNAs are identified at > 10 counts in 50% of samples, and 25 miRNAs with > 10 counts were 
found in 100% of the samples. 336 miRNAs were detected at least once in a saliva sample with > 10 counts, and 
141 and 69 miRNAs were detected with > 10 counts in 50% and 100% of saliva samples. There are surprisingly 
few miRNAs consistently detected in all samples. Supplementary Table 4 summarizes the miRNAs detected in all 
samples. In this table, we describe the number of samples in which each miRNA was detected, for each biofluid. 
We also display the level of expression for that miRNA in each biofluid.
Figure 3. Distribution of miRNAs in biofluids. Panel A is a principal components analysis of the miRNAs 
detected in each biofluid. Each biofluid has a distinct miRNA pattern. Panel B displays the miRNAs detected 
in each biofluid with > 10 or > 50 counts in at least 80% of the samples. There are only a handful of miRNAs 
uniquely detected in urine and saliva at this level of expression. Most miRNAs can be detected in plasma. (C) 
shows the number of detected miRNAs at 1 count, 10 counts or 50 counts, as a function of input reads. (D) 
shows the number of reads mapped to the human genome as a function of the input reads. Saliva samples 
require larger numbers of input reads to achieve the same numbers of reads aligned to the genome as plasma 
and urine. Urine samples behave similarly to plasma samples with respect to input reads that map to the genome 
(D), but have fewer miRNAs detected (C).
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Limit of detection of miRNAs. The analysis for detection of miRNAs in Table 4 depends on read depth and the 
complexity of miRNAs and other small RNAs in the sample. Each library loaded onto the sequencer has some 
variability in read depth, and the amount of rRNA and other RNA biotypes present in the sample can alter the 
number of reads that align to the genome and to miRNA. Using some of the libraries loaded with higher than 
expected read depth, we can calculate how many miRNAs are detected with increasing library size. Figure 3C 
displays the number of miRNAs observed as a function of input reads. The samples are binned by one million 
read increments. The median number of detected miRNAs for each bin with greater than 1, 10 and 50 read counts 
are plotted. As expected, the solid line depicts the increase in the number of miRNAs detected as a logarithmic 
function with respect to the sequencing depth. For the plasma samples, an increase in the sequencing depth from 
10–11 million reads to greater than 20 million reads adds another 64 miRNAs that are detected with at least 50 
read counts. However, for the urine samples, a commensurate increase in sequencing depth adds only 17 miR-
NAs detected with 50 counts. For saliva, doubling the sequencing depth from 4–6 million reads to greater than 
10 million reads adds 78 miRNAs detected with at least 50 counts. Saliva samples require many more input reads 
to achieve meaningful levels of reads mapped to the human genome, and therefore to the detection of miRNAs 
(Fig. 3D).
miRNAs with highest and lowest CVs. We next wanted to assess how similar the samples within each biofluid 
were to each other, and if the samples were taken from the same individual, were they more similar than when 
compared to the samples from the whole group. We examined data from individuals that provided more than 5 
samples over time (11 individuals provided > 5 plasma samples and 5 individuals provided > 5 urine samples). It 
should be noted, the samples obtained from an individual were not equally distributed in time, a collection period 
could span 69 weeks. We did not have > 5 saliva samples sequenced from any individuals, and therefore did not 
include an analysis. The miRNA read counts for all samples were normalized for library size using the median 
ratio method.
The coefficient of variation (CV) was calculated to assess the dispersion of miRNA expression among all of the 
samples sequenced, and multiple samples collected from the same individuals. In this analysis we included only 
well-expressed miRNAs, > 50 read counts and detected in at least 80% of the samples. The box plots in Fig. 4A 
display the distribution of miRNA CV values for each individual sampled at least 5 times. The distribution of 
the miRNA CVs for the “All samples” boxplot takes into account one sample per individual. The boxplots for 
the individuals depict intra-individual variance and the last boxplot for “All samples” represents inter-individual 
variance. For urine, the intra-individual miRNA variation is significantly less than the inter-individual variation. 
A two-sided Wilcoxon rank sum test reveals that this difference is statistically significant, with p-values < 0.05 for 
all individuals and p-value < 0.001 for individuals 1, 2, 3 and 4 (See Fig. 4A). miRNAs detected in the plasma sam-
ples had a wider range of variability, higher (star) and lower (asterisk) CV than the samples from all individuals.
Figure 4B,C display the 15 miRNAs with the lowest CVs (4B) and highest CVs (4C) for all three biofluids 
across all samples sequenced. miRNAs that were in common between at least two biofluids are bolded and under-
lined, only one miRNA was highlighted for all biofluids. miR-1246 had a high CV in all biofluids. Box plots in 
Supplementary Figure S2 display the top 15 miRNAs with the lowest CV and highest CV for individuals (5 miR-
NAs overlap in the analysis of the lowest CVs and 5 miRNAs overlap in the calculated highest CVs).
Detailed exogenous RNA analysis. We did not directly target exogenous RNA sequences in our samples. 
However, we assessed the potential bacterial content in the samples using GOTTCHA; Genomic Origin Through 
Taxonomic CHAllenge40. GOTTCHA is a profiling tool that uses read-based metagenome characterization fol-
lowing a hierarchical collection of exclusive signatures at multiple taxonomic levels such as strain-level, species, 
genus, family, order, class and phylum. Owing to similarity in genomic regions, such as 16S rRNA, coding regions 
and other highly conserved regions, metagenomic identification typically yields results with a high false discovery 
rate (FDR). We used the precompiled bacterial database available at ftp://ftp.lanl.gov/public/genome/gottcha/ 
consisting of unique species-level genomic signatures that was produced by eliminating shared 24-mer (k24) 
Plasma Detected miRNA Urine Detected miRNA Saliva Detected miRNA
 > 10 counts > 50 counts > 10 counts > 50 counts > 10 counts > 50 counts
Detected in at least 1 sample 975 585 545 299 336 144
Detected in 10% 472 271 191 102 200 107
Detected in 20% 396 237 171 87 179 95
Detected in 30% 363 211 146 80 163 86
Detected in 40% 340 201 131 70 154 84
Detected in 50% 329 190 122 66 141 79
Detected in 60% 306 177 110 64 132 76
Detected in 70% 287 171 104 59 123 72
Detected in 80% 257 162 92 54 116 63
Detected in 90% 213 132 79 46 103 59
Detected in 100% 98 82 25 19 69 37
Table 4.  Number of miRNAs detected in each biofluid. The number of miRNAs detected > 10 or > 50 counts 
in at least one sample of plasma, urine, or saliva samples, or in 10, 20, 30, 40 − > 100% of samples.
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Figure 4. Coefficient of variation for multiple samples taken from the same individual compared with 
the coefficient of variation from all subjects. (A) displays the distribution of CVs calculated for each miRNA 
detected at > 50 counts in at least 80% of the plasma and urine samples. Some of the individual subjects1–11 that 
provided more than 5 samples for sequencing over the course of ~70 weeks, show a closer distribution of CVs 
when compared to samples from all subjects (asterisk). And some of the subjects with > 5 samples display a 
higher CV than when examining all subjects at once (star). Distribution of miRNA counts for the 15 miRNAs 
with the lowest CV (B) and the highest CV (C) in each biofluid. At this time, we are unable to determine if the 
CVs are related to biological variability or to technical variability.
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sequences from 4937 bacterial replicons (includes both chromosomes and plasmids) and the human genome, 
while retaining a minimum of 24 bp of unique fragments. When mapped to the species-level database, the reads 
are rolled up to the next higher taxonomic orders, which are genus, family, order, class and phylum. Further elim-
ination of false positives entail that the organism discovered must have a minimum of 100 non-overlapping bases 
covering the unique genomic signature, a coverage of at least 0.5% and at least 10 hits to the unique signature. 
These stringent requirements allow for the identification of bacteria in the biofluid samples with a potentially low 
false positive rate. Out of the 161 plasma exRNA samples sequenced, only 9 samples had at least one significant 
species of bacteria detected. Only two species of bacteria was seen in 4 or more samples: Candidatus Tremblaya 
princeps and Brucella melitensis. One sample had 315 species of bacteria present, with the highest read counts 
going to Desulfovibrio vulgaris, Pyrococcus furiosus, Singulisphaera acidiphila, Rhodopirellula baltica, Asticcacaulis 
excentricus and Synechococcus sp. WH 8102 Desulfobacca acetoxidans.
66 out of the 159 urine exRNA samples had at least one significant species of bacteria detected. Escherichia 
coli was seen in 7 samples and only three species of bacteria was seen in > 25% of the 66 samples: Achromobacter 
xylosoxidans, Gardnerella vaginalis and Streptococcus pneumonia, with 22, 20 and 17 samples respectively. 
One sample had 1433 species of bacteria present; with the highest read counts going to Prevotella intermedia, 
Singulisphaera acidiphila, Micrococcus luteus, Arthrobacter phenanthrenivorans and Amycolicicoccus subflavus. A 
large number of bacterial species are seen in the saliva samples.
There are 110 bacterial species seen in at least 22 of the 30 saliva samples (75% of the saliva samples sequenced). 
The top ten most highly detected bacteria are: Rothia mucilaginosa, Prevotella melaninogenica, Dyadobacter fer-
mentans, Streptococcus salivarius, Methanolacinia petrolearia, Bacillus megaterium, Anaerobaculum mobile, 
Singulisphaera acidiphila and Rothia dentocariosa. In the saliva samples, an average of ~45.5% of the reads mapped 
uniquely to bacterial species (after adapter trimming and removing reads that were < 15 nts). Table 5 provides a 
snapshot of the species most commonly detected and in what number of samples. Supplementary Table S3 has a 
more thorough analysis of the bacterial species detected using GOTTCHA.
Biofluid TAXA
Number of 
samples Average RPM
Plasma
Brucella melitensis 5 2.6
Candidatus Tremblaya princeps 4 17.5
Thermus sp. CCB_US3_UF1 3 45.2
Candidatus Tremblaya phenacola 3 29.2
Propionibacterium acnes 2 313.9
Synechococcus sp. PCC 6312 2 21.0
Pseudomonas monteilii 2 38.2
Streptococcus suis 2 22.5
Sphingomonas sp. MM-1 2 6.1
Listeria monocytogenes 2 6.5
Urine
Achromobacter xylosoxidans 22 1655.1
Gardnerella vaginalis 20 376.1
Streptococcus pneumoniae 17 147.1
Streptococcus suis 16 56.6
Thermus sp. CCB_US3_UF1 16 22.6
Candidatus Tremblaya phenacola 14 26.4
Salmonella enterica 12 36.3
Candidatus Tremblaya princeps 12 23.7
Microcoleus sp. PCC 7113 10 282.7
Cyanothece sp. PCC 7425 10 179.8
Saliva
Rothia mucilaginosa 29 3623.6
Streptococcus salivarius 29 1894.9
Prevotella melaninogenica 29 2400.2
Dyadobacter fermentans 15 4544.9
Bacillus megaterium 19 1440.5
Methylacidiphilum infernorum 19 1513.4
Methanolacinia petrolearia 17 2164.8
Vibrio vulnificus 19 911.6
Sulfobacillus acidophilus 14 1386.6
Singulisphaera acidiphila 14 1658.6
Table 5.  List of exogenous species detected by GOTTCHA. List of exogenous species detected by 
GOTTCHA. The 10 most prevalent bacterial species (detected in the largest number of samples) for each 
biofluid, are displayed. The number of samples the bacteria was detected in and the expression (RPM = reads 
mapping to the unique bacterial genomic signature divided by the input number of reads > = 15 nts) are shown.
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Discussion
This is the largest dataset examining extracellular RNA expression, and the presence of different RNAs, to date. 
As we are deciphering what quality metrics differentiate a good sample from a bad sample – and what should 
be expected from extracellular RNA samples, more data sets are required. Different isolation, sequencing, and 
analysis tools will need to be applied to large data sets so that we can accurately gauge the true signature from 
technical artifact. In addition, more data exploring a significant range of age and gender will be important. The 
Extracellular RNA Communication Consortium (ERCC) is actively developing an extensive atlas for normal 
extracellular RNAs from biofluids, and from several diseases and injuries. The dataset described here will be 
deposited in the atlas where it can be compared with other samples examining extracellular RNAs (the data can 
also be found in dbGaP, accession # phs001258.v1.p1).
We analyzed this data for several key abundant RNA biotypes, however, there are several more biotypes that 
could be explored using this data9,10. Each biofluid appears to have clear differences in extracellular RNA expres-
sion profiles. For example, there appears to be a high proportion of tRNA fragments in urine samples, when 
compared with other RNA biotypes. In particular, there is one fragment that has very high read counts. It would 
be interesting to know if the tissues in closest proximity to urine (kidney, bladder, adrenal gland) had very high 
levels of this tRNA or the fragment. Or, perhaps the increased proportion of the fragments in urine is due to some 
filtering mechanism for that biofluid. Better small RNA tissue atlases that include more comprehensive profiles of 
the small RNA species will be necessary to help answer these questions.
Unique sequences that align exclusively to piRNA in urine and saliva samples are very low. It is not possible 
to say that there are no piRNA in these biofluids, but their origin and overlap with other RNA biotypes will have 
to be carefully examined.
We assessed YRNAs, which accounted for ~63% of the reads mapping to the genome for plasma samples. It is 
unclear what the role these 5 prime YRNA fragments have in normal healthy individuals, but they are found in 
significant abundance. The Gingeras laboratory recently observed that RNY5 fragments, found in vesicles isolated 
from cancer cells, could trigger cell death18. Urine (0.7%) and saliva (0.5%) samples did not show such high levels 
of YRNA fragments.
miRNAs are the most diverse RNA biotype found in biofluid samples. Most of the miRNAs could be detected 
in plasma, with few unique miRNAs in urine and saliva. While almost 1000 miRNAs could be detected in all 
plasma samples, if we required higher stringency - that they be detected in most samples (80%) with at least 
modest expression levels (> 10 counts), the number of miRNAs in the analysis went down dramatically. Because 
sequencing does pick up such large numbers of other small RNAs (YRNA, tRNA, etc.), a more targeted approach 
to miRNA detection may reveal a larger number of miRNAs consistently expressed.
Not surprisingly, saliva had a large number of reads going to bacterial species. The largest category of reads 
aligned to the human genome for the saliva samples was, unassigned, meaning that most reads were to intergenic, 
intronic or were sequences that mapped to > 40 places in the genome and could not be assigned to any location. 
More reads actually aligned to bacterial species than to the human genome. We used an algorithm, GOTTCHA, 
to detect bacteria in our samples40. Urine samples had some bacterial species identified, and only a handful of 
samples had a large diversity of bacteria detected. This analysis was interesting and showed few plasma samples 
that had detectable levels of bacteria. There was one plasma sample that had 315 bacterial species detected at low 
levels, likely due to contamination. In future experiments, additional negative controls should be examined to 
verify that the bacterial species came from the biofluid samples, and not contamination from subject skin, collec-
tion process, isolation or kit preparations.
As we examine extracellular RNA profiles in biofluids, we are looking for consistent RNAs that can be detected 
with confidence in each biofluid, as well as normal levels of expression for comparison to disease and injury. We 
found that miRNAs from urine, that were assessed more than 5 times from the same individuals over a years 
time frame, were closer together than when examining the miRNA dispersion in samples taken from all subjects. 
This was not the case for plasma samples, where some individuals had higher and lower variability over time 
than when compared to all subjects. This may indicate that establishing a baseline for individuals when they are 
healthy may provide the most meaningful comparisons when exploring early indicators of disease, severity, or 
outcome. While we cannot determine at this time if the lowest and highest CVs are due to technical or biological 
variability, we believe this is worth keeping track of as more large datasets become available. For example, miR-
1246 was found to have one of the highest CVs in each biofluid. Does this miRNA reflect rapid turnover and 
changes in response to biological events, or significant technical variability due to sample collection, handling or 
sequencing? As more large datasets examining the full profile of extracellular RNAs found in biofluids emerge, 
it will be important to learn what variables alter the detection of RNAs. As more individuals share their samples, 
analysis and classification schemes, other researchers can improve upon the methods to increase accuracy and 
remove variability from the analysis. Therefore, we have tried to provide the most comprehensive profile of the 
most abundant RNA species detected in our samples using current tools and databases. This information will be 
essential as the field moves toward using these expression changes for the detection of health, disease, and injury.
Materials and Methods
Samples. Samples were collected from male college athletes ages 18–25. All human subjects provided writ-
ten consent form prior to enrollment. All samples were collected with consent and approval from the Western 
Instiutional Review Board (WIRB) study ID# 1307009395. Small RNA profiling experiments from human sam-
ples were performed at the Translational Genomics Research Institute (TGen) in accordance with the regulations 
and proper approval from WIRB. Blood samples were collected in EDTA tubes and placed in a cooler with ice 
packs until they were transported from Arizona State University (ASU) to TGen, within 2–3 hours of blood draw. 
Samples were spun down at 2500 RPM for 10 minutes at 4 °C. Plasma was aliquotted at 1 mL volumes into 2 mL 
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RNase/DNase free Microcentrifuge tubes (VWR), and stored at − 80 °C. Urine was collected in sterile cups and 
placed in a cooler with ice, and transported to TGen within 2–3 hours of collection. Samples were spun at 3000 
RPM for 10 minutes at 4 °C and aliquotted 15 mL into a 50 mL conical tube for storage at − 80 °C. Saliva samples 
were collected by allowing passive drool to collect and spitting into a 50 mL conical tube. The sample was spun at 
3000 RPM for 10 minutes at 4 °C, aliquotted as 1 mL volumes into 2 mL microcentrifuge tubes and stored at − 80 °C.
RNA Isolation. For all plasma and saliva samples we isolated 1 mL of biofluid. Samples were isolated using the 
mirVana miRNA Isolation Kit (ThermoFisher Scientific, AM1560) according to Burgos et al., 201341. Samples were 
DNase treated using TURBO DNA-free Kit (ThermoFisher Scientific, AM1907). Because of residual phenol/chlo-
roform, samples were then cleaned and concentrated using Zymo RNA Clean and Concentrator (Zymo Research, 
R1016) using Protocol: Purification of small and large RNAs into separate fractions and combining the fractions 
at the end. All urine samples (15 mL) were isolated using Urine Total RNA Purification Maxi Kit, Slurry Format 
(Norgen Biotek Corp., Cat#29600). Samples were DNase treated on column using RNase-Free DNase Set (Qiagen, 
cat# 79254). Because there was no residual phenol/chloroform, samples were concentrated by Speed Vacuum.
Sequencing. All sequencing data is available through the ERCC exRNA Atlas and through accession num-
ber phs001258.v1.p1 in dbGaP. The plasma, saliva and urine RNA were quantified in triplicate using Quant-iT 
Ribogreen RNA Assay kit, Low-Range protocol (R11490; ThermoFisher). The Illumina small RNA TruSeq kit 
(RS-200–0048; Illumina) was used for sequencing all samples. RNA input for plasma and saliva was 10–20 ng for 
all samples and the RNA input for urine was 30 ng for all samples. The reagents from the Illumina TruSeq kit were 
halved, as in Burgos et al., 2013. Each sample was assigned one of 48 possible indices. We used 16 PCR cycles for 
all samples. Indexed samples were run on a gel and purified away from the adaptor band. The samples were then 
pooled and placed on Illumina V3 single read flowcells (GD-401-3001; Illumina). The average read counts at each 
nucleotide length for each biofluid is displayed in Supplementary Figure S3.
RNA-Seq data analysis. The raw sequence image files from the Illumina HiSeq 2500 in the form of bcl are 
converted to the fastq format using bcltofastq v1.8.4 and checked for quality to ensure the quality scores do not 
Sequence Read Counts
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCTCTCACCG 95
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCTCTCACC 3
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCTCTCAC 5
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCTCTCA 6
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCTCTC 3,752
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCTCT 14,528
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCTC 13,967
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCT 68,915
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGC 329,486
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCG 50,571
Collapsed Sequence Total
TCCCTGGTGGTCTAGTGGTTAGGATTCGGCGCTCTCACCG 482,479
Table 7. Example for the collapse of tRNA sequences.
Library type Version and notes
rRNA
Mt_rRNA sequences from Ensembl 75 (ENST00000389680, ENST00000387347), rRNA sequences for the 12S 
rRNA (gi|407595|gb|S64650.1), RNA5-8S5 (NR_003285.2), RNA5S4 to RNA5S17, RNA18S5 (NR_003286.2), 
RNA28S5 (NR_003287.2), RNA45S5 (NR_046235.1)
miRNA miRBase v.21. Consists of 2587 human miRNA entries
tRNAs
gtRNAdb, hg19. Consists of 624 entries. The mature tRNA sequences were obtained after removing the introns 
using tRNAscan-SE (Lowe, T.M. and Eddy, S.R. (1997) Nucleic Acids Res, 25: 955–964.). After removal of 
introns, the bases “CCA” were added to the 3′ end as would be expected for a mature tRNA (tRFdb: A database 
for transfer RNA fragments, Nov, 2104). Also, 50 bp flanking both the 3′ and the 5′ were included
piRNAs pirBase v.1.0. Consists of 32827 human piRNAs
All RNA from Gencode
hg19, ENSEMBL 75
Consists of the following RNA biotypes:
Protein coding, Mt-tRNA, Mt-rRNA, snoRNA, snRNA, VaultRNA, YRNA and other non-coding RNA. This 
latter category is a collective for 3prime_overlapping_ncRNA, antisense, IG_C_gene, IG_C_psuedogene, 
IG_D_gene, IG_J_gene, IG_J_psuedogene, IG_V_gene, IG_V_psuedogene, lincRNA, LRG_gene, misc_RNA, 
polymorphic_psuedogene, processed_psuedogene, psuedogene, sense_intronic, sense_overlapping, TR_C_
gene, TR_D_gene, TR_J_gene, TR_J_psuedogene, TR_V_gene, TR_V_psuedogene
Sequence Read Counts
Table 6.  Database of RNA biotypes used.
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deteriorate drastically at the read ends. The adapters from the 3′ end are clipped using cutadapt v.1.10 (http://cut-
adapt.readthedocs.io/en/stable/guide.html). Reads shorter than 15 nts are discarded and after adapter trimming, 
the 3′ bases below a quality score of 30 are trimmed as well. All subsequent steps are carried out using sRNABench 
(http://bioinfo5.ugr.es/sRNAbench/sRNAbench.php), which provides an elegant framework to map the reads 
to various RNA libraries using Bowtie1 to perform the alignments. The reads are first mapped to human rRNA 
sequences obtained from NCBI and those that map are removed from analysis. The algorithm used in sRNABench 
is based on the mirAnalyzer42, where the reads with the same sequence are collapsed and mapped to the human 
genome and miRNA database. A single base mismatch and a seedlength of 19 nts are used for this step. The reads 
that remain after mapping to the miRNA database are then mapped to mature tRNAs, piRNAs and all other RNAs 
in ENSEMBL 75. Here, there is no mismatch allowed and each read is allowed to multimap to at most 40 RNA 
annotations. Table 6 provides the list of libraries used and their versions.
Analysis of the tRNA fragments (tRFs). All reads that map to mature tRNAs are used for the analysis. 
The reads, based on their read sequence are stacked as shown in Table 7 and the read counts for all reads that share 
the same 5 prime or 3 prime end are added up for that particular tRNA. For example, the following fragments 
arise from the 5′ end of mature tRNA GluCTC. There are 8 mature GluCTC tRNAs with identical 5′ ends. These 
fragments are now “collapsed” to their longest sequence and all read counts are added up (bottom row).
The fragments that arise from the 5 prime and the 3 prime end of the mature tRNAs are termed tRF5s and 
tRF3s respectively. Fragments that arise from neither of these two ends are termed tRFMs (tRF middle). This gives 
rise to a list of fragments with unique sequences whose source on the mature tRNA (tRF5, tRF3 and tRFU), the 
length distribution and the type of tRNA fragment (ValCAC, GlyGCC, etc) are now known.
Analysis of YRNA fragments. Analysis was carried out in the same manner as tRNA analysis.
Analysis of the exogenous bacterial species. The precompiled bacterial database available at ftp://ftp.
lanl.gov/public/genome/gottcha/ consisting of unique species-level genomic signatures that was produced by 
eliminating shared 24-mer (k24) sequences from 4937 bacterial replicons (includes both chromosomes and plas-
mids) and the human genome, while retaining a minimum of 24 bp of unique fragments was used. All the param-
eters used for filtering out false positives were the default parameters in GOTTCHA.
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